Gene Silencing Market Report 2026

The gene silencing market size has grown rapidly in recent years. It will grow from $6.69 billion in 2025 to $7.53 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to advancement in molecular biology research, discovery of rna interference mechanisms, expansion of academic research funding, growth in genetic disease studies, increased pharmaceutical r&d spending.

The gene silencing market size is expected to see rapid growth in the next few years. It will grow to $12.1 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to growth of gene therapy pipelines, rising demand for targeted therapeutics, expansion of crispr applications, increased clinical trial activity, development of next-generation gene editing tools. Major trends in the forecast period include growing adoption of rna interference technologies, increasing use of crispr-based gene silencing, expansion of therapeutic gene targeting, rising focus on precision medicine applications, increasing investment in genetic research.

The increasing prevalence of genetic disorders is expected to drive the growth of the gene silencing market in the coming years. Genetic disorders are medical conditions that arise from abnormalities in an individual’s DNA. These conditions are being identified more frequently due to advancements in diagnostic technologies, greater awareness, and wider availability of genetic testing. The rise in genetic disorders is largely attributed to increasing parental age, which raises the likelihood of genetic mutations being transmitted to offspring. Gene silencing provides a promising therapeutic strategy by selectively inhibiting the expression of defective or disease-causing genes. For instance, in August 2023, according to Down Syndrome UK, a UK-based charity, an estimated 40,000 individuals in the UK are affected by Down syndrome, with around 1 in every 800 babies born with the condition. Therefore, the growing prevalence of genetic disorders is fueling the expansion of the gene silencing market.

Major companies operating in the gene silencing market are concentrating on the development of innovative technologies, such as small interfering RNA (siRNA), to improve precision and effectiveness in gene therapy. Small interfering RNA (siRNA) is a class of RNA molecules involved in the RNA interference (RNAi) pathway that binds to specific messenger RNA (mRNA) sequences and induces their degradation, thereby preventing the production of disease-causing proteins. For instance, in October 2024, Judo Bio Inc., a US-based biotechnology company, launched a next-generation siRNA-based therapy designed to silence target genes. This approach incorporates proprietary delivery technologies, including lipid nanoparticles and conjugated ligands, to enable efficient and targeted cellular uptake, along with AI-driven platforms that accelerate the identification of viable gene targets.

In September 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Decibel Therapeutics for an undisclosed amount. With this acquisition, Regeneron aims to strengthen its genetic medicine and gene therapy capabilities, particularly in the treatment of sensory disorders such as genetic hearing loss. Decibel Therapeutics is a US-based company dedicated to developing gene therapies for hearing loss, including its lead program DB-OTO, which employs a gene silencing approach.

Major companies operating in the gene silencing market are Roche Holding AG, Merck & Co. Inc., AstraZeneca plc, Novartis International AG, Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Bio-Techne Corporation, Alnylam Pharmaceuticals Inc., GenScript Biotech Corporation, Oxford BioMedica plc, Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., New England Biolabs Inc., Quark Pharmaceuticals Inc., Sirion Biotech GmbH, Benitec Biopharma Limited, GeneCopoeia Inc., Revvity Inc.

North America was the largest region in the gene silencing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene silencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene silencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the gene silencing market by increasing the cost of imported oligonucleotides, reagents, and laboratory instruments used in gene modulation research. These impacts have been most pronounced in pharmaceutical and academic research segments in North America and Europe. Asia-Pacific markets have faced higher research input costs due to import dependencies. However, tariffs have encouraged regional manufacturing of genetic research tools and reagents.

The gene silencing market research report is one of a series of new reports that provides gene silencing market statistics, including gene silencing industry global market size, regional shares, competitors with a gene silencing market share, detailed gene silencing market segments, market trends and opportunities, and any further data you may need to thrive in the gene silencing industry. This gene silencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene silencing is a biological process in which the expression of a specific gene is reduced or completely suppressed. It plays a vital role in regulating gene activity, controlling development, and defending against viral infections. Gene silencing is particularly important in research and medicine for targeting genes associated with disease.

The main types of gene silencing include transcriptional, post-transcriptional, and meiotic. Transcriptional gene silencing relates to processes that affect transcription, the synthesis of RNA from a DNA template. Gene-silencing approaches include RNA interference (RNAi), antisense oligonucleotides (ASOs), clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene silencing, and others. These techniques are applied in areas such as neurology, oncology, infectious diseases, metabolic disorders, and therapeutic manufacturing, and are used by pharmaceutical and biotechnology companies, research institutes and academic centers, hospitals, clinics, and other end users.

The gene silencing market consists of revenues earned by entities by providing services such as services such as gene knockdown assays, RNAi screening services, and epigenetic gene silencing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cholestatic pruritus market also includes sales of small interfering RNA, miRNA mimics and inhibitors, reporter assay kits, and therapeutic RNAi-based drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.